Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Confidence Interval
100%
Patients with Cancer
100%
Cancer Metastasis
100%
Meta-analysis
100%
Skeletal Metastases
100%
Skeletal-related Events
100%
Denosumab
100%
Risk Ratio
85%
Zoledronic Acid
57%
Adverse Events
42%
Overall Survival
28%
Hazard Ratio
14%
MEDLINE
14%
Embase
14%
No Significant Difference
14%
Quality of Life
14%
Bone Metastasis
14%
Literature Search
14%
Low Incidence
14%
Bone Turnover Markers
14%
Systematic Literature Review
14%
Web of Science
14%
Overall Mortality
14%
Event Time
14%
Hypocalcemia
14%
Osteonecrosis of the Jaw
14%
Cochrane Collaboration
14%
Event Risk
14%
Pain Level
14%
Controlled Clinical Trial
14%
Medicine and Dentistry
Metastatic Carcinoma
100%
Bone Metastasis
100%
Meta-Analysis
100%
Systematic Review
100%
Denosumab
100%
Zoledronic Acid
57%
Adverse Event
42%
Overall Survival
28%
Hazard Ratio
14%
Quality of Life
14%
Controlled Clinical Trial
14%
Bone Turnover
14%
Independent Reviewer
14%
Osteonecrosis of the Jaw
14%
Hypocalcaemia
14%
Pharmacology, Toxicology and Pharmaceutical Science
Bone Metastasis
100%
Denosumab
100%
Zoledronic Acid
57%
Adverse Event
42%
Overall Survival
28%
Controlled Clinical Trial
14%
Hypocalcaemia
14%
Jaw Osteonecrosis
14%
Immunology and Microbiology
Denosumab
100%
Overall Survival
28%
Web of Science
14%
Jaw
14%
Bone Turnover
14%